The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

By Kamal Choudhury (Reuters) -Novavax shares jumped more than 15% on Monday after the company secured a long-awaited U.S.

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

Key Takeaways Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine.The shot, ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...

US Food and Drug Administration officials are changing the agency's standards for updated COVID-19 booster shots with focus ...

Novavax (NVAX) shares climbed more than 17% premarket on Monday after the long-delayed approval of its COVID-19 vaccine from ...

The FDA has approved Novavax’s protein-based COVID-19 vaccine, giving some Americans another option besides messenger RNA vaccines to prevent SARS-CoV-2 infection.

The FDA has approved Novavax’s COVID-19 vaccine, Nuvavoxid, for use in adults 65 and older and in individuals ages 12-64 who have at least one underlying health condition. The approval is based on ...

The U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Novavax Inc.’s Nuvaxovid.

April 25, 2025 US FDA asks Novavax to complete new clinical trial for delayed COVID-19 shot, WSJ reports Federal regulators have asked Novavax to complete an additional clinical trial on its COVID ...